cancer therapy
drug development
innovative therapy
cancer patients
new therapy
Feasibility study
gene therapy
recombinant peptide therapy Peptomyc
multiple cancer models
multiple cancer markets
business development plan
different drug products
Peptomyc’s products
recombinant peptides
drug substance
innovative anti-Myc peptides
Omomyc-CPP
Peptomyc’s team
Myc inhibitor
GBM
commercialization of OMO
completion of phase
IND applications
successful phase
different administration routes
execution of safety studies
clinical trials coordination
remarkable therapeutic impact
unexpected cell-penetrating properties
formulations
effects
years of preclinical validation
efficacy
excellent candidates
class
majority of human cancers
delivery devices
risk analyses
strong asset
novel treatment
pharmaceutical company
licensing deal
care
glioblastoma
SME
best CRO partners
regulatory requirements
Selection
costs
oncogene
Refinement
emergence of resistance
commercial potential
Management
IPR strategy
EMA Briefing meeting
mission